Invenra Inc. is pleased to announce the launch of its Rapid Bispecific Antibody Discovery Services. Utilizing Invenra’s B-Body® Bispecific Platform, the streamlined service can identify bispecific antibody lead panel candidates in as little as four months.

With these accelerated services, Invenra continues to build on its reputation for groundbreaking, client-focused discovery models. Recognizing the critical need for faster timelines in preclinical antibody discovery, the service is designed to meet the growing demand for expedited preclinical discovery on time-sensitive projects.

“Our team is committed to accelerating bispecific antibody discovery without compromising quality or precision,” said Roland Green, CEO. “This new approach harnesses our advanced technologies and refined workflows, empowering both established and early-stage biopharmaceutical companies to meet ambitious timelines and bring innovative treatments to patients faster.”

The new rapid discovery service complements Invenra’s established role as a strategic partner in antibody discovery and development. For those seeking a comprehensive partnered approach, Invenra continues to offer tailored support across all discovery stages, including custom antigen design, cell line generation, assay development, and in-depth biological analysis - each customized to meet the unique objectives of its partner.

About Invenra

Invenra Inc. provides innovative pharmaceutical discovery and development services, specializing in antibody discovery and development for a range of therapeutic applications. For more information, please visit invenra.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241203531890/en/